Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia
暂无分享,去创建一个
A. Advani | M. Sekeres | Barbara Tripp | M. Kalaycio | E. Copelan | R. Sobecks | R. Tiu | K. Theil | G. Ramsingh | W. Saber | T. Jin | Shawnda Sungren
[1] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.
[2] Jiong Hu,et al. NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis , 2006, Clinical Cancer Research.
[3] E. Thiel,et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.
[4] T. Naoe,et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia , 2006, Cancer.
[5] K. Faber,et al. Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia , 2005, Clinical Cancer Research.
[6] C. Bloomfield,et al. Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. , 2005 .
[7] D. Scheinberg,et al. A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL , 2005 .
[8] Thomas Flohr,et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.
[9] J. Cayuela,et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Michael N Dworzak,et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.
[11] C. Bloomfield,et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. , 1999, Blood.
[12] R. Larson,et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.
[13] M. Andreeff,et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Ganser,et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. , 1988, Blood.
[15] R. Dinsmore,et al. Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. , 1986, Critical reviews in oncology/hematology.
[16] M. Andreeff,et al. Acute lymphoblastic leukemia in adults. , 1985, Seminars in oncology.